RETROVIRAL TRANSFER OF THE N1SLACZ GENE INTO HUMAN CD34(+) CELL-POPULATIONS AND INTO TF-1 CELLS - FUTURE-PROSPECTS IN GENE-THERAPY

被引：29

作者：

BAGNIS, C ^{[1
]}

GRAVIS, G ^{[1
]}

IMBERT, AM ^{[1
]}

HERRERA, D ^{[1
]}

ALLARIO, T ^{[1
]}

GALINDO, R ^{[1
]}

LOPEZ, M ^{[1
]}

PAVON, C ^{[1
]}

SEMPERE, C ^{[1
]}

MANNONI, P ^{[1
]}

机构：

[1] INSERM,U119,F-13273 MARSEILLE,FRANCE

来源：

HUMAN GENE THERAPY | 1994年 / 5卷 / 11期

关键词：

D O I：

10.1089/hum.1994.5.11-1325

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Few data are available concerning behavior of reimplanted human hematopoietic cells after autologous stem cell transplantation. This paper reports the possibility to transfer gene markers coding for beta-galactosidase (beta-Gal) activity by retroviral vectors into a human leukemic growth factor-dependent cell line, TF-1, and into human hematopoietic progenitors isolated from peripheral blood or bone marrow. Using various combinations of retroviral vectors and packaging cell lines, we demonstrated high expression of a bacterial beta-Gal activity induced by the LacZ gene, the nlsLacZ gene, or the Sh-ble/LacZ gene, in human hematopoietic cells. The expression of the nlsLacZ construct was stable until the end of the culture in infected CD34(+) cell-enriched cell populations, and a slow decrease of transgene expression was observed in a transduced TF-1 cell population during a 1-year long-term culture. Data obtained with the nlsLacZ gene demonstrate that both retroviral transfer and corresponding gene expression were not found to modify the pattern of cell proliferation and differentiation. These results open interesting prospectives for the use of the nlsLacZ gene to mark and follow the fate of progenitor cells isolated from patients with cancers prior to reimplantation.

引用

页码：1325 / 1333

页数：9

共 37 条

[21] CONSTRUCTION AND USE OF A SAFE AND EFFICIENT AMPHOTROPIC PACKAGING CELL-LINE [J].